MedPath

XYWAV

XYWAV

Approved
DIN Number

02538237

Drug Class

Human

Market Date

Oct 4, 2023

Company
HC

JAZZ PHARMACEUTICALS IRELAND LIMITED

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02538237
AIG Number0464702001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule G (CDSA I)
A
ATC Code
N07XX04 HYDROXYBUTYRIC ACID
Product Specifications
Dosage FormSolution
Route of AdministrationOral
AHFS Classification28:92.00
Health Canada Classification

ACTIVE INGREDIENTS (4)

CALCIUM OXYBATEActive
Strength: 0.234 G / ML
Monograph: CALCIUM OXYBATE
MAGNESIUM OXYBATEActive
Strength: 0.096 G / ML
Monograph: MAGNESIUM OXYBATE
POTASSIUM OXYBATEActive
Strength: 0.13 G / ML
Monograph: POTASSIUM OXYBATE
SODIUM OXYBATEActive
Strength: 0.04 G / ML
Monograph: SODIUM OXYBATE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.